Xconomy: With BioNTech Deal, Pfizer Becomes Latest to Bet on mRNA Vaccines | Enterpreneurship
This morning, the New York pharma company cut a deal with BioNTech, of Germany, to co-develop mRNA vaccines for flu prevention.
BioNTech will run the initial human tests on these treatments, then hand the programs off to Pfizer (NYSE: PFE) for further development.
Through an unspecified upfront cash payout, equity, and research payments, BioNTech could net a total of $120 million in the near-term for signing the deal. It could ultimately see another $305 million in downstream… Read more »
UNDERWRITERS AND PARTNERS